Literature DB >> 29098992

Identifying prognostic factors in chronic obstructive pulmonary disease patients.

Maria-Teresa Garcia-Sanz1.   

Abstract

Entities:  

Year:  2017        PMID: 29098992      PMCID: PMC5684804          DOI: 10.4103/lungindia.lungindia_354_17

Source DB:  PubMed          Journal:  Lung India        ISSN: 0970-2113


× No keyword cloud information.
Chronic obstructive pulmonary disease (COPD) is a major cause of mortality worldwide.[1] Baseline disease severity, acute exacerbations of COPD (AECOPD), and a number of comorbidities increase short- and long-term mortality risk.[2345] Other prognostic factors vary across studies, probably due to differences in analyzed populations, collected variables, and statistical methods. Despite worldwide research on health-care efforts and costs, statistics show an increasing trend in mortality, in contrast with other relevant causes of death.[6] Identifying patients at high risk of death and modifiable predictors of mortality is therefore of importance for both patients and health-care providers, to optimize therapeutic strategies and COPD management. In this issue of Lung India, Koul et al.[7] reported a prospective observational study conducted in a tertiary care hospital to determine the postdischarge mortality of patients surviving an AECOPD and analyze factors associated with mortality. The investigators reported 151 patients who were discharged after a hospital admission due to AECOPD (64% male, mean age 65 years). These patients were managed with oxygen, steroids, bronchodilators, antibiotics, and invasive or noninvasive ventilation. About 32.4% died during 1 year and 39.7% at 2 years of follow-up. The factors associated with mortality were lower health status (St. George's Respiratory Questionnaire [SGRQ] score >60), heart failure, worse lung function (GOLD), 6-min walk distance (6MWD) <150 m, and frequent exacerbations. Despite the study was carried out in a single center, some of the results reported are consistent with recent publications. Koul et al.[7] reported that COPD mortality was 39.7%. Previous studies on long mortality for COPD have shown a 2-year mortality from 27.9% to 85.5%.[891011] Comorbidities and lung function seem to be strongly associated with COPD mortality.[312] COPD is often accompanied by relevant comorbidities such as hypertension, heart failure, atrial fibrillation, ischemic heart disease, cerebrovascular accident, diabetes, chronic kidney or liver disease, cancer, dementia, depression, anxiety, and lower body mass index.[313] Frequently, its prevalence is bigger than expected,[14] and multiple comorbidities had accumulative effect on mortality.[15] However, the underlying causes of multimorbidity in COPD are not yet completely recognized. Cardiovascular comorbidities and COPD share similar risk factors and common pathophysiological mechanisms.[16] Heart disease, hypertension, and diabetes are associated with increased systemic inflammation,[15] and the presence of systemic inflammation, evaluated for selected biomarkers, adds prognostic value and establishes clinical variables to predict mortality in COPD.[17] Data in the ECLIPSE study identified five COPD subgroups that differ in outcomes and inflammatory biomarkers.[18] Comorbidity associated with COPD is partially responsible of increased mortality, and patients hospitalized for AECOPD ranked high in the Charlson scale and had lower survival rates.[19] This fact implies that there is a need to identify those comorbidities which are more strongly associated with an increased risk of death in COPD patients. However, the management of major chronic co-morbidities in COPD patients is not clearly established. Among patients with COPD, lower health status was associated with an increased risk of adverse outcomes including death.[20] Koul et al.[7] measured the relationship between baseline health status and mortality using the SGRQ and showed that COPD patients having SGRQ >60 had higher mortality than those with SGRQ scores of ≤60. A previous study by Müllerova et al.[21] confirmed that baseline SGRQ status predicts mortality risk, suggesting health status measurement provides additional prognostic information independent of other factors. The increased mortality in COPD patients is related with frequency and intensity of AECOPD, especially those exacerbations requiring hospitalization.[2] The risk of death is bigger in those with a greater number of exacerbations per year. Koul et al.[7] report that frequent exacerbations occurred in 31.8% of COPD patients, and frequent exacerbations were related to the severity of COPD according to the GOLD stage. Decreased FEV1 and static hyperinflation predict exercise capacity and both had been associated with increased mortality.[2223] 6MWD is a variable derived from the 6-min walking test,[24] commonly used to assess functional exercise capacity in patients with COPD. A 6MWD <350 m has been shown to independently predict mortality in COPD patients.[2526] Koul et al.[7] confirm that 6MWD will help to identify COPD patients at risk of death. The current study by Koul et al., taken together with data from other cohorts, highlights the need to identify patients with very poor prognosis potentially requiring more careful attention.
  25 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

2.  Patients admitted to the ICU for acute exacerbation of COPD: two-year mortality and functional status.

Authors:  Cassiano Teixeira; Cláudia da Rocha Cabral; Jaqueline Sangiogo Hass; Roselaine Pinheiro de Oliveira; Mara Ambrosina de Oliveira Vargas; Ana Paula da Rocha Freitas; Alessandra Hofstadler Deiques Fleig; Erika Cristine Treptow; Márcia Inês Boff Rizzotto
Journal:  J Bras Pneumol       Date:  2011 May-Jun       Impact factor: 2.624

3.  St George's Respiratory Questionnaire Score Predicts Outcomes in Patients with COPD: Analysis of Individual Patient Data in the COPD Biomarkers Qualification Consortium Database.

Authors:  Hana Müllerova; Heather Gelhorn; Hilary Wilson; Victoria S Benson; Niklas Karlsson; Shailendra Menjoge; Stephen I Rennard; Maggie Tabberer; Ruth Tal-Singer; Debora Merrill; Paul W Jones
Journal:  Chronic Obstr Pulm Dis       Date:  2017-03-28

4.  Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort.

Authors:  Joy Miller; Lisa D Edwards; Alvar Agustí; Per Bakke; Peter M A Calverley; Bartolome Celli; Harvey O Coxson; Courtney Crim; David A Lomas; Bruce E Miller; Steve Rennard; Edwin K Silverman; Ruth Tal-Singer; Jørgen Vestbo; Emiel Wouters; Julie C Yates; William Macnee
Journal:  Respir Med       Date:  2013-06-19       Impact factor: 3.415

5.  Validation and comparison of reference equations for the 6-min walk distance test.

Authors:  C G Cote; C Casanova; J M Marín; M V Lopez; V Pinto-Plata; M M de Oca; L J Dordelly; H Nekach; B R Celli
Journal:  Eur Respir J       Date:  2007-11-07       Impact factor: 16.671

6.  Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis.

Authors:  Stephen I Rennard; Nicholas Locantore; Bruno Delafont; Ruth Tal-Singer; Edwin K Silverman; Jørgen Vestbo; Bruce E Miller; Per Bakke; Bartolomé Celli; Peter M A Calverley; Harvey Coxson; Courtney Crim; Lisa D Edwards; David A Lomas; William MacNee; Emiel F M Wouters; Julie C Yates; Ignacio Coca; Alvar Agustí
Journal:  Ann Am Thorac Soc       Date:  2015-03

Review 7.  Systemic manifestations and comorbidities of COPD.

Authors:  P J Barnes; B R Celli
Journal:  Eur Respir J       Date:  2009-05       Impact factor: 16.671

8.  Association of heart diseases with COPD and restrictive lung function--results from a population survey.

Authors:  Berne Eriksson; Anne Lindberg; Hana Müllerova; Eva Rönmark; Bo Lundbäck
Journal:  Respir Med       Date:  2012-11-03       Impact factor: 3.415

9.  Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease.

Authors:  Bartolome R Celli; Nicholas Locantore; Julie Yates; Ruth Tal-Singer; Bruce E Miller; Per Bakke; Peter Calverley; Harvey Coxson; Courtney Crim; Lisa D Edwards; David A Lomas; Annelyse Duvoix; William MacNee; Stephen Rennard; Edwin Silverman; Jørgen Vestbo; Emiel Wouters; Alvar Agustí
Journal:  Am J Respir Crit Care Med       Date:  2012-03-15       Impact factor: 21.405

10.  The Prognostic Value of Residual Volume/Total Lung Capacity in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Tae Rim Shin; Yeon-Mok Oh; Joo Hun Park; Keu Sung Lee; Sunghee Oh; Dae Ryoung Kang; Seungsoo Sheen; Joon Beom Seo; Kwang Ha Yoo; Ji-Hyun Lee; Tae-Hyung Kim; Seong Yong Lim; Ho Il Yoon; Chin Kook Rhee; Kang-Hyeon Choe; Jae Seung Lee; Sang-Do Lee
Journal:  J Korean Med Sci       Date:  2015-09-12       Impact factor: 2.153

View more
  1 in total

1.  Variation in body mass index in patients with chronic obstructive pulmonary disease.

Authors:  Mukesh S Paudel; Amrendra Mandal; Paritosh Kafle; Jasdeep S Sidhu; Pradeep Puri; Baikuntha Chaulagai; Azad Mojahedi; Vijay Gayam
Journal:  J Family Med Prim Care       Date:  2019-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.